Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05NDN
|
|||
| Former ID |
DNC000177
|
|||
| Drug Name |
Alovudine
|
|||
| Synonyms |
Alovudine; 25526-93-6; FddT; 3'-DEOXY-3'-FLUOROTHYMIDINE; FddThD; 3'-Fluoro-3'-deoxythymidine; Thymidine, 3'-deoxy-3'-fluoro-; 3'F-TdR; 3'-FddT; Alovudine [USAN:INN]; UNII-PG53R0DWDQ; 3'-Fluorothymidine; 3'-FLT; DRG-0097; PG53R0DWDQ; NSC 140025; BRN 0754299; 3'-Fluorodeoxythymidine; CL 184824; CHEMBL105318; FLT; 1-((2R,4S,5R)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; C10H13FN2O4; MIV-310; 1-(3'-Deoxy-3'-fluoro-beta-D-pentofuranosyl)thymine; CL-184824; DSSTox_RID_81738; DSSTox_CID_26579
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H13FN2O4
|
|||
| Canonical SMILES |
CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)F
|
|||
| InChI |
1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1
|
|||
| InChIKey |
UXCAQJAQSWSNPQ-XLPZGREQSA-N
|
|||
| CAS Number |
CAS 25526-93-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
595893, 8172954, 12014132, 14774145, 15221019, 17396987, 24862180, 34674983, 50054706, 50618601, 57311462, 68536877, 85202976, 91693945, 99299689, 103321186, 104023306, 104315122, 124343161, 126665390, 129433032, 134224699, 134339685, 134996084, 137156948, 137240496, 142354881, 144205929, 152057204, 162239272, 164839118, 170466324, 179150230, 198987252, 223395142, 223666099, 223725084, 224923940, 226501917, 249771531, 252543093
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02232581) Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure. U.S. National Institutes of Health. | |||
| REF 2 | Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.